Stock Trading Canary

United States · SEC Form 4 · Snapshot date: 2026-10-18 · Built: 2026-10-18 · 中文

← United States · Coverage record

US · SEC FORM 4

Pyxis Oncology, Inc.

PYXS · Nasdaq · CIK 0001782223 · Healthcare · Biotechnology

INSIDER SIGNAL

No active buy signal

1 qualifying P purchase group
in the current 180-day scoring window

3 Form 4 transaction lines observed in the same window
1 sales · 1 option, withholding, award, gift or other lines

Last qualifying purchase2026-10-01 · Gordon Craig D; GordonMD Global Investments LP; GordonMD Long Biased GP LLC; GordonMD Long Biased Master Fund LP · value unavailable

WHY NO ACTIVE SIGNAL?

Purchase activityPresent
Recent buying1 qualifying line group(s)
Recent salesLow
Buy signal statusInactive
Score anatomy

No score is calculated because there is no qualifying purchase in the active window. Unavailable inputs are not treated as zero or as a bearish signal.

ClusterNot calculated
Purchase sizeNot calculated
RoleNot calculated
RecencyNot calculated
ConvictionNot calculated

Why is there no score?

  • No qualifying open-market purchase supplies cluster, size, role, recency or conviction inputs.
  • Sales and other Form 4 activity remain visible as context and do not create a negative score.

Sales and other Form 4 activity are shown separately and do not create a negative buy signal. Absence of buying is not scored as bearish.

Insider activity timeline

Owner lanes show the latest 180 days. Symbol shape identifies the transaction type; sales remain context only.

AprMayJunJulAugSepOct
Dupont JakobDirector
○▼
Gordon Craig D; GordonMD Global Investments LP; GordonMD Long Biased GP LLC; GordonMD Long Biased Master Fund LPTenPercentOwner
●
● Purchase▼ Sale○ Other

—

Purchase breadth & concentration

QUALIFYING BUYERS1
PURCHASE CONCENTRATION—Largest buyer: Gordon Craig D; GordonMD Global Investments LP; GordonMD Long Biased GP LLC; GordonMD Long Biased Master Fund LP · $0
CLUSTER BUYING · 15D1 insiderPeak activity: 2026-10-01–2026-10-01

Roles in the peak window: TenPercentOwner. Concentration uses priced qualifying P lines only and does not change the saved score.

SIGNAL HISTORY

No recorded active-signal snapshot

Scores are archived only when the company qualifies for a published US buy-signal snapshot. Last qualifying purchase: 2026-10-01 · Gordon Craig D; GordonMD Global Investments LP; GordonMD Long Biased GP LLC; GordonMD Long Biased Master Fund LP.

Recent Form 4 activity

1Purchases
1Sales
2Other Form 4 lines
3SEC filings · 365 days
BUYING1 qualifying P line(s) · 180 days
SELLING1 sale line(s) · context only
OTHER1 exercise / withholding / award / gift / other lines
10b5-1 / PLANNEDNot assessed

P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.

Market context

Market context has not been captured for this ticker yet. The daily market-context job processes the US universe in rotating batches.

Short interest

Short interest is external context reported to FINRA by broker-dealers. It does not affect the Insider Signal.

Shares short
4,886,652
Previous report
4,678,522
Avg daily volume
1,207,832
Days to cover
4.0

FINRA settlement date: 2026-09-30 · Captured 2026-10-12 · FINRA equity short interest ↗. A share count, published about a week after each of two settlement dates a month; not a percentage of shares outstanding.

Historical equity purchases

Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.

Transaction dateReporting ownerTypeSecuritySharesAvg. priceApprox. valueSource
2026-10-01Gordon Craig D; GordonMD Global Investments LP; GordonMD Long Biased GP LLC; GordonMD Long Biased Master Fund LPPurchase (P)Common Stock, par value $0.001 per share ("Common Stock")5,517,000USD —USD —SEC filing ↗
2024-11-26Connealy Pamela AnnPurchase (P)Common Stock88,850USD 1.96USD 174,364SEC filing ↗
2023-09-28Connealy Pamela AnnPurchase (P)Common Stock8,000USD 1.87USD 14,960SEC filing ↗
2023-09-27Wadhane JitendraPurchase (P)Common Stock2,500USD 1.87USD 4,675SEC filing ↗
2023-09-27Connealy Pamela AnnPurchase (P)Common Stock6,426USD 1.85USD 11,888SEC filing ↗
2023-09-25Wadhane JitendraPurchase (P)Common Stock5,000USD 1.77USD 8,850SEC filing ↗
2023-09-25Connealy Pamela AnnPurchase (P)Common Stock12,000USD 1.67USD 20,040SEC filing ↗
2023-09-22Wadhane JitendraPurchase (P)Common Stock2,500USD 1.74USD 4,350SEC filing ↗
2023-09-22Connealy Pamela AnnPurchase (P)Common Stock5,000USD 1.74USD 8,700SEC filing ↗
2023-03-17PFIZER INC; Pfizer Ventures (US) LLCPurchase (P)Common Stock, $0.001 par value per share1,811,594USD 2.76USD 4,999,999SEC filing ↗
2023-03-17PFIZER INC; Pfizer Ventures (US) LLCPurchase (P)Common Stock, $0.001 par value per share1,811,594USD 2.76USD 4,999,999SEC filing ↗
2021-12-08Cline Darren SPurchase (P)Common Stock10,000USD 9.39USD 93,900SEC filing ↗
2021-11-18Civik ThomasPurchase (P)Common Stock15,700USD 12.74USD 200,018SEC filing ↗
2021-10-13Chin MarkPurchase (P)Common Stock312,500USD 16.00USD 5,000,000SEC filing ↗
2021-10-13Chen Bihua; Cormorant Asset Management, LP; Cormorant Global Healthcare Master Fund, LP; Cormorant Private Healthcare Fund III LPPurchase (P)Common Stock450,000USD 16.00USD 7,200,000SEC filing ↗

Form 4 evidence

4 transaction lines in the latest 365-day window; 71 in local history.

DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-10-01Gordon Craig D; GordonMD Global Investments LP; GordonMD Long Biased GP LLC; GordonMD Long Biased Master Fund LPPurchase (P)Common Stock, par value $0.001 per share ("Common Stock")5,517,000USD —USD —SEC filing ↗
2026-06-30Dupont JakobSale (S)Common Stock35,000USD 3.06USD 107,100SEC filing ↗
2026-06-30Dupont JakobOption exercise / conversion (M)Common Stock35,000USD 1.60USD 56,000SEC filing ↗
Show recent Form 4 evidence (4 grouped rows)
DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-10-01Gordon Craig D; GordonMD Global Investments LP; GordonMD Long Biased GP LLC; GordonMD Long Biased Master Fund LPPurchase (P)Common Stock, par value $0.001 per share ("Common Stock")5,517,000USD —USD —SEC filing ↗
2026-06-30Dupont JakobSale (S)Common Stock35,000USD 3.06USD 107,100SEC filing ↗
2026-06-30Dupont JakobOption exercise / conversion (M)Common Stock35,000USD 1.60USD 56,000SEC filing ↗
2026-03-24Wadhane JitendraAward / grant (A)Common Stock109,461USD 0.00USD 0SEC filing ↗

Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.

Snapshot & identity

Snapshot date2026-10-18
Ranking versionUS-v1.2
Data qualityPASS ELIGIBLE · —
TickerPYXS
CIK0001782223
SectorHealthcare
IndustryBiotechnology Yahoo Finance
SEC SIC2834 Pharmaceutical Preparations
ExchangeNasdaq

Data coverage

Local Form 4 history71 transaction lines from 2021-10-07 to 2026-10-01
16 P purchase lines · 10 S sale lines · 45 other lines
SEC company submissionsOpen SEC filings ↗

Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.